Technology Coaching Intervention for Black Women With Hypertension
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03577990 |
|
Recruitment Status :
Completed
First Posted : July 5, 2018
Last Update Posted : October 28, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Uncontrolled Hypertension | Behavioral: ITEC Behavioral: No ITEC | Not Applicable |
This study includes a sample of community dwelling Black women with uncontrolled HTN. All participants meeting study eligibility requirements will receive the Chronic Disease Self-Management Program (CDSMP) workshop for 6 weeks. Participants from this pool will be randomized to the treatment and control arm. All study participants will continue to receive usual care for their HTN.
The intervention will be divided into three steps. At Step 1 for 3 months, the treatment arm will receive electronic monitoring (of participants' BP, weight, physical activity, food diary, and medication-taking) with weekly Interactive Technology Enhanced Coaching (ITEC) while the control arm will receive usual care with manual BP measurements monthly. At Step 2 for three months, the treatment arm will receive electronic monitoring with ITEC biweekly, and the control arm will receive electronic monitoring only. At Step 3 for three months, both the treatment arm and the control arm will receive electronic monitoring only.
Our sample of n=45 participants per arm (N=90 in total), will be measured (electronic measurements, anthropometric measurements, and data collection tools) at baseline, 3 months, 6 months, and at 9 months post CDSMP. A hierarchical, mixed-effects repeated measures design will be used to analyze the data.
The project is a two-arm randomized controlled trial with specific aims to determine whether the effects of CDSMP combined with ITEC will maintain BP control, attain medication adherence, and achieve lifestyle modifications (physical activity, diet, and weight management) compared to the CDSMP alone. We will test the hypothesis that:
- More participants in the CDSMP/ITEC arm will have controlled BP less than 130/80 at 3 months, 6 months, and at 9 months post CDSMP, compared to participants in CDSMP alone.
- More participants in the CDSMP/ITEC arm will have higher levels of adherence to antihypertensive medication(s) at 3 months, 6 months, and at 9 months post CDSMP, compared to participants in the CDSMP alone.
- More participants in the CDSMP/ITEC arm, will have higher levels of adherence to lifestyle modifications (physical activity, diet, and weight management) at 3 months, 6 months, and at 9 months post CDSMP, compared to participants in the CDSMP alone.
Information from this study may be used to enhance self-care management, control blood pressure, and increase the quality of life for Black women who are burdened with the adverse effects of HTN and its high disability and mortality rates.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 90 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | The study will test the effects of ITEC added to CDSMP on two study aims: 1) BP control, and 2) adherence to antihypertensive medication and lifestyle modifications. After baseline data collection, participants complete a 6-week CDSMP course and then are randomly assigned to either the treatment or control arm. All participants will continue to receive usual care for HTN. The treatment group will receive ITEC and wireless tools to track activity, BP, weight, food intake, and self-report medication-taking after an orientation to Fitbit Plus (a cloud-based collaborative care platform designed to store and track data). All tools will be synced to the participants' smartphone. The treatment arm will receive weekly ITEC for 3 months, biweekly ITEC for 3 months, and then no ITEC for 3 months. The control arm will receive usual care only with monthly BP measured manually for 3 months and then receive the same wireless tools with monitoring to track comparative data with the treatment arm. |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Interactive Technology Enhanced Coaching Intervention for Black Women With Hypertension |
| Actual Study Start Date : | January 28, 2019 |
| Actual Primary Completion Date : | April 16, 2021 |
| Actual Study Completion Date : | April 16, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ITEC
Fitbit Plus monitoring will include BP, weight measurements, daily food intake, self-report medication-taking, and physical activity plus weekly Interactive Technology-Enhanced Coaching (ITEC) for 3 months, then biweekly ITEC for 3 months, followed by another 3 months with no coaching to assess for sustainability.
|
Behavioral: ITEC
As participants wear the activity tracker, take their BP and weight, along with input of food intake and medication-taking, data is transmitted in real time via Bluetooth Smart technology to the Fitbit Plus dashboard. All data is tracked, analyzed, and transparently displayed for participants to view and better understand their condition, and actively engage in self-care. Staff monitor data and communicate with participants to encourage active engagement in action plans by sending tailored coaching messages (ITEC) via the Fitbit Plus dashboard to the treatment arm weekly for 3 months, and biweekly for 3 months to motivate and support (BP control, medication adherence, and lifestyle modifications). After 6 months, the treatment arm will be monitored an additional 3 months with no tailored coaching for sustainability. |
|
Active Comparator: No ITEC
Participants will receive usual care for 3 months followed by 6 months of only Fitbit Plus monitoring (with no ITEC) of BP, weight measurements, daily food intake, self-report medication-taking, and physical activity to be used for comparative data with the treatment arm.
|
Behavioral: No ITEC
After receiving usual care for 3 months, the control arm will receive the same electronic monitoring as the treatment arm and data will be captured in the same manner with the Fitbit Plus dashboard. Participants will be expected to use the information from the dashboard and the CDSMP workshop as a guide to self-care without ITEC. Staff will only monitor data. Control participants will not be contacted between repeated measures data collection periods, except to send reminders if they are not participating daily. |
- Change in Systolic and Diastolic Blood Pressure (BP) [ Time Frame: Study participants will be assessed for changes at baseline, 3 months, 6 months, and 9 months. ]BP will be measured according to the American Heart Association Guidelines for home BP monitoring. Track daily BP measurements electronically for changes and compare with Self-Care of Hypertension Inventory, Self-Efficacy for Managing Chronic Disease, and Healthcare Utilization tools.
- Medication Adherence [ Time Frame: Assess for changes at baseline, 3 months, 6 months, and 9 months. ]Compare daily self-reported medication adherence electronically and with Hill-Bone High Blood Pressure Compliance Scale to change in BP.
- Physical activity [ Time Frame: Assess for changes at baseline, 3 months, 6 months, and 9 months. ]Compare daily steps using Fitbit activity tracker electronically to change in BP.
- Diet Tracking [ Time Frame: Assess for changes at baseline, 3 months, 6 months, and 9 months. ]Compare daily self-reported caloric intake electronically to change in BP.
- Weight Management [ Time Frame: Assess for changes at baseline, 3 months, 6 months, and 9 months. ]Compare daily weight measurement electronically to change in BP.
- Stigma and Hypertension [ Time Frame: Baseline ]Qualitative stigma questionnaire (includes two open-ended questions, no scale) to gain insight and describe the psychological factor of stigma as an influence on poorly controlled HTN in Black women.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Self-identified as Black or African American;
- 18-70 years of age
- English speaking
- Has to live in the study community, Charlotte or surrounding area
- Systolic BP greater than or equal to 130 and/or diastolic BP greater than or equal to 80 at screening
- Prescribed to take one or more antihypertensive medication(s)
- Smartphone or device
- Bluetooth 4.0 and Provider network or Wi-Fi connectivity
Exclusion Criteria:
- Self-report of mental illness that interferes with daily functioning
- Unable to be physically active
- Current pregnancy
- Plans to move from the study area during the project
- Systolic BP greater than or equal to 160 and/or diastolic BP greater than or equal to 100
- Uncontrolled diabetes (HbA1c >8.5), hemodialysis, stroke (within past year with residual effects such as weakness, paralysis, speech difficulty, etc.), cancer treatment (for spread of cancer to other places in the body), or a heart attack (within the past year)
- Concurrent participation in another research study and/or taken any Stanford self-management program
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03577990
| United States, North Carolina | |
| Churches, Salons, Community Events | |
| Charlotte, North Carolina, United States, 28223 | |
| Principal Investigator: | Willie M Abel, PhD | The University of North Carolina at Charlotte | |
| Study Director: | Mark J DeHaven, PhD | The University of North Carolina at Charlotte |
| Responsible Party: | Willie Abel, Assistant Professor, University of North Carolina, Charlotte |
| ClinicalTrials.gov Identifier: | NCT03577990 |
| Other Study ID Numbers: |
17-0549 1K01HL140288 ( U.S. NIH Grant/Contract ) |
| First Posted: | July 5, 2018 Key Record Dates |
| Last Update Posted: | October 28, 2021 |
| Last Verified: | October 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
hypertension, Black women, self-management, coaching |
|
Hypertension Vascular Diseases Cardiovascular Diseases |

